Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS (Voclosporin) in Japan
Portfolio Pulse from Benzinga Newsdesk
Aurinia Pharmaceuticals Inc. announced that its partner Otsuka Pharmaceutical filed an NDA in Japan for LUPKYNIS (voclosporin) for lupus nephritis treatment. The FDA approved voclosporin in January 2021 for LN in the U.S. Under a collaboration agreement, Aurinia will receive $10 million upon Japan approval and royalties on sales.
November 13, 2023 | 11:01 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aurinia Pharmaceuticals may see a financial benefit from the NDA filing in Japan by its partner Otsuka, with a potential $10 million payment and future royalties on sales.
The filing of the NDA in Japan by Otsuka is a significant regulatory step that could lead to market expansion for LUPKYNIS. The potential approval in Japan represents a direct financial incentive for Aurinia Pharmaceuticals, as it stands to receive a $10 million payment and royalties. This news is likely to be viewed positively by investors, as it indicates progress in the commercialization of voclosporin and potential revenue growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100